Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

IVAX Corporation (IVX)

  Print      Mail a friend

Wednesday 06 August, 2003

IVAX Corporation

Response to: IVAX Confirms First to File Generic S

Response to: IVAX Confirms First to File Generic Submission on Lexapro 

    LONDON--(BUSINESS WIRE)--Aug. 6, 2003--

In response to enquiries and speculation arising out of a report
earlier this week that an unknown generic company had filed a generic
drug application containing a patent challenge to Forest Laboratories'
Lexapro(TM), IVAX Corporation (AMEX:IVX) (LSE:IVX.L) confirms that it
has filed an Abbreviated New Drug Application on escitalopram oxalate
in 5, 10, and 20 mg tablet dosage strengths, containing a Paragraph IV
certification. Escitalopram oxalate is the generic equivalent of
Lexapro, which is marketed by Forest Laboratories to treat depression.
U.S. sales of Lexapro for the first quarter of 2003 were $154.7
million and have increased to $217.7 million in the second quarter of
2003, according to IMS figures. IVAX believes that it is first to file
on escitalopram oxalate.

IVAX continues its aggressive program to increase the number of
products in its generic portfolio.

IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and

Copies of this and other news releases may be obtained free of
charge from IVAX' website at

Except for the historical matters contained herein, statements in
this press release are forward-looking and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Investors are cautioned that forward-looking statements,
including the statements regarding IVAX' first to file status and
ability to increase the number of products in its generic portfolio,
involve risks and uncertainties which may affect IVAX' business and
prospects. Such risks and uncertainties include: the difficulty in
predicting the timing and outcome of legal proceedings, including
those relating to patent challenge settlements and patent infringement
cases; the difficulty of predicting the timing of U.S. Food and Drug
Administration, or FDA, approvals; court and FDA decisions on
exclusivity periods; that IVAX may not have first to file status;
competitor's ability to extend exclusivity periods past initial patent
terms; that IVAX may not receive approval for escitalopram oxalate or
that its launch will be delayed; or that if approved, the products
will not be successfully commercialized; that IVAX may not file any
additional ANDAs; changing market conditions; the availability and
cost of raw materials and other third party products; the impact of
competitive products and pricing and other risks and uncertainties
based on economic, competitive, governmental, technological and other
factors discussed in IVAX' Annual Report on Form 10-K and its other
filings with the Securities and Exchange Commission. Lexapro(TM) is a
trademark of Forest Laboratories.

   Short Name: IVAX Corporation
   Category Code: RSP
   Sequence Number: 00008059
   Time of Receipt (offset from UTC): 20030806T160747+0100


a d v e r t i s e m e n t